Autonomic dysfunction in parkinsonian LRRK2 mutation carriers
Beatriz Tijero(University of the Basque Country), J.J. Zarranz(University of the Basque Country), Johanne Somme(University of the Basque Country), Trinidad Rodríguez(Hospital de Cruces), Juan Carlos Gómez‐Esteban(University of the Basque Country), Elena Lezcano(University of the Basque Country), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Verónica Llorens(Hospital de Cruces), Koldo Berganzo(University of the Basque Country)
Cited by 30
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293